Jesse J Fryk1, Denese C Marks1, Jody Hobson-Peters2, Natalie A Prow2,3, Daniel Watterson2, Roy A Hall2, Paul R Young2, Stefan Reichenberg4, Chryslain Sumian5, Helen M Faddy6,7. 1. Research and Development, Australian Red Cross Blood Service, Australia. 2. Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, and the. 3. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 4. MacoPharma International GmbH, Langen, Germany; and. 5. MacoPharma, Mouvaux, France. 6. Research and Development, Australian Red Cross Blood Service, Australia. hfaddy@redcrossblood.org.au. 7. School of Medicine, The University of Queensland, Brisbane, Queensland, Australia. hfaddy@redcrossblood.org.au.
Abstract
BACKGROUND: Arboviruses, such as dengue viruses (DENV) and chikungunya virus (CHIKV), pose a risk to the safe transfusion of blood components, including plasma. Pathogen inactivation is an approach to manage this transfusion transmission risk, with a number of techniques being used worldwide for the treatment of plasma. In this study, the efficacy of the THERAFLEX MB-Plasma system to inactivate all DENV serotypes (DENV-1, DENV-2, DENV-3, DENV-4) or CHIKV in plasma, using methylene blue and light illumination at 630 nm, was investigated. STUDY DESIGN AND METHODS: Pooled plasma units were spiked with DENV-1, DENV-2, DENV-3 DENV-4, or CHIKV and treated with the THERAFLEX MB-Plasma system at four light illumination doses: 20, 40, 60, and 120 (standard dose) J/cm(2) . Pre- and posttreatment samples were collected and viral infectivity was determined. The reduction in viral infectivity was calculated for each dose. RESULTS: Treatment of plasma with the THERAFLEX MB-Plasma system resulted in at least a 4.46-log reduction in all DENV serotypes and CHIKV infectious virus. The residual infectivity for each was at the detection limit of the assay used at 60 J/cm(2) , with dose dependency also observed. CONCLUSIONS: Our study demonstrated the THERAFLEX MB-Plasma system can reduce the infectivity of all DENV serotypes and CHIKV spiked into plasma to the detection limit of the assay used at half of the standard illumination dose. This suggests this system has the capacity to be an effective option for managing the risk of DENV or CHIKV transfusion transmission in plasma.
BACKGROUND: Arboviruses, such as dengue viruses (DENV) and chikungunya virus (CHIKV), pose a risk to the safe transfusion of blood components, including plasma. Pathogen inactivation is an approach to manage this transfusion transmission risk, with a number of techniques being used worldwide for the treatment of plasma. In this study, the efficacy of the THERAFLEX MB-Plasma system to inactivate all DENV serotypes (DENV-1, DENV-2, DENV-3, DENV-4) or CHIKV in plasma, using methylene blue and light illumination at 630 nm, was investigated. STUDY DESIGN AND METHODS: Pooled plasma units were spiked with DENV-1, DENV-2, DENV-3 DENV-4, or CHIKV and treated with the THERAFLEX MB-Plasma system at four light illumination doses: 20, 40, 60, and 120 (standard dose) J/cm(2) . Pre- and posttreatment samples were collected and viral infectivity was determined. The reduction in viral infectivity was calculated for each dose. RESULTS: Treatment of plasma with the THERAFLEX MB-Plasma system resulted in at least a 4.46-log reduction in all DENV serotypes and CHIKV infectious virus. The residual infectivity for each was at the detection limit of the assay used at 60 J/cm(2) , with dose dependency also observed. CONCLUSIONS: Our study demonstrated the THERAFLEX MB-Plasma system can reduce the infectivity of all DENV serotypes and CHIKV spiked into plasma to the detection limit of the assay used at half of the standard illumination dose. This suggests this system has the capacity to be an effective option for managing the risk of DENV or CHIKV transfusion transmission in plasma.
Authors: Ángel Giménez-Richarte; Mabel Ortiz de Salazar; Cristina Arbona; María P Giménez-Richarte; Miriam Collado; Pedro L Fernández; Francisco Quiles; Carlos Clavijo; Pascual Marco; Jose-Manuel Ramos-Rincon Journal: Blood Transfus Date: 2021-09-22 Impact factor: 5.752
Authors: Ahmed M Ashshi; Saad Alghamdi; Adel G El-Shemi; Sabir Almdani; Bassem Refaat; Amr M Mohamed; Hani O Ghazi; Esam I Azhar; Faisal A Al-Allaf Journal: Virology (Auckl) Date: 2017-02-24
Authors: José Luis Arroyo; Eva Martínez; Cristina Amunárriz; Carmen Muñoz; Iñigo Romón; Ignacio Álvarez; José María García Journal: Transfus Apher Sci Date: 2020-04-12 Impact factor: 1.764
Authors: Layla Pires; Brian C Wilson; Rod Bremner; Amanda Lang; Jeremie Larouche; Ryan McDonald; Joel D Pearson; Daniel Trcka; Jeff Wrana; James Wu; Cari M Whyne Journal: Sci Rep Date: 2022-08-24 Impact factor: 4.996
Authors: Kelly Rooks; Clive R Seed; Jesse J Fryk; Catherine A Hyland; Robert J Harley; Jerry A Holmberg; Denese C Marks; Robert L P Flower; Helen M Faddy Journal: J Blood Transfus Date: 2016-11-13
Authors: Mathieu Gendrot; Julien Andreani; Isabelle Duflot; Manon Boxberger; Marion Le Bideau; Joel Mosnier; Priscilla Jardot; Isabelle Fonta; Clara Rolland; Hervé Bogreau; Sébastien Hutter; Bernard La Scola; Bruno Pradines Journal: Int J Antimicrob Agents Date: 2020-10-16 Impact factor: 15.441